0A7L Stock Chart & Stats
$112.39
$2.69(2.39%)
At close: 4:00 PM EDT
$112.39
$2.69(2.39%)
Day’s Range― - ―
52-Week Range$97.71 - $206.00
Previous CloseN/A
Volume16.00
Average Volume (3M)53.00
Market Cap
$3.85B
Enterprise Value$4.02K
Total Cash (Recent Filing)$591.27M
Total Debt (Recent Filing)$727.35M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Oct 29, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding32,862,408
10 Day Avg. Volume49
30 Day Avg. Volume53
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)37.18
Price to Sales (P/S)7.60
P/FCF Ratio164.50
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$174.50Price Target Upside55.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$881.14M
Bulls Say, Bears Say
Bulls Say
High Gross Margin & Product EconomicsSustained ~70%+ gross margins reflect a high-value device plus cloud analytics model and recurring per-episode revenue. Durable product economics provide room for reinvestment and margin expansion as volume scales, supporting long-term cash generation and competitive pricing flexibility.
Improving Cash GenerationShift to consistently positive operating cash flow and record quarterly free cash flow shows the business is converting revenue into liquidity. Strong cash reserves improve runway for R&D, regulatory spend, and M&A while reducing reliance on external financing over the next several quarters.
Platform Expansion Via VitalConnectBuying VitalConnect materially diversifies offerings into multi-parameter and inpatient continuous monitoring, broadening addressable market and cross-sell opportunity. Structural product expansion reduces single-modality exposure and can lift enterprise contracts and long-term revenue mix resilience.
Bears Say
High Financial LeverageA debt-heavy capital structure (nearly 4x D/E) constrains financial flexibility and increases sensitivity to revenue or margin shocks. Higher interest and principal obligations may limit strategic investments, raise refinancing risk, and reduce resilience to cyclical payer or reimbursement changes.
Outstanding FDA Warning LetterAn unresolved FDA warning letter is a durable regulatory overhang that can restrict product introductions, increase compliance costs, and create uncertainty around new-clearance timelines (e.g., Zio MCT). Prolonged regulatory scrutiny can delay adoption and revenue realization for quarters.
Legal & Settlement Cash BurdensMaterial litigation and settlement payments reduce available cash and may exhaust insurance protections, limiting capital for growth and M&A. Recurring legal exposure and associated cash outflows represent a persistent drag on free cash flow and increase governance and compliance costs.
Irhythm Technologies News
0A7L FAQ
What was Irhythm Technologies’s price range in the past 12 months?
Irhythm Technologies lowest share price was $97.71 and its highest was $206.00 in the past 12 months.
What is Irhythm Technologies’s market cap?
Irhythm Technologies’s market cap is $3.85B.
When is Irhythm Technologies’s upcoming earnings report date?
Irhythm Technologies’s upcoming earnings report date is Oct 29, 2026 which is in 83 days.
How were Irhythm Technologies’s earnings last quarter?
Irhythm Technologies released its earnings results on Aug 06, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.03.
Is Irhythm Technologies overvalued?
According to Wall Street analysts Irhythm Technologies’s price is currently Undervalued.
Does Irhythm Technologies pay dividends?
Irhythm Technologies does not currently pay dividends.
What is Irhythm Technologies’s EPS estimate?
Irhythm Technologies’s EPS estimate is 0.03.
How many shares outstanding does Irhythm Technologies have?
Irhythm Technologies has 32,862,408 shares outstanding.
What happened to Irhythm Technologies’s price movement after its last earnings report?
Irhythm Technologies reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Irhythm Technologies?
Currently, no hedge funds are holding shares in GB:0A7L
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Irhythm Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$174.50 (55.26% Upside)
$174.50 (55.26% Upside)
Blogger Sentiment
Bullish
GB:0A7L Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.67%
Trailing 12-Months
Company Description
Irhythm Technologies
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
0A7L Company Deck
0A7L Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: high‑teens to low‑20% organic revenue growth, record profitability and free cash flow, raised guidance, constructive reimbursement news, and a strategic acquisition (VitalConnect) that expands modality, market opportunity and multivital capabilities. Notable risks discussed include an outstanding FDA warning letter, a recent cybersecurity incident, a $50 million litigation settlement, integration and regulatory review risks related to the VitalConnect acquisition, and the pending clearance of the company’s Zio MCT product. On balance, positive execution, margin expansion, and clear strategic rationale for the acquisition outweigh the manageable regulatory and integration headwinds.View all GB:0A7L earnings summaries0A7L Stock 12 Month Forecast
Average Price Target
$174.50
▲(55.26% Upside)